GQ 1012
Alternative Names: GQ-1012Latest Information Update: 11 Jul 2024
At a glance
- Originator Suzhou GeneQuantum Healthcare
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 05 Apr 2024 Preclinical trials in Solid tumours in China (IV), prior to April 2024
- 05 Apr 2024 Adverse events, pharmacokinetics and pharmacodynamics data from a preclinical trials in Solid tumours presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 11 Jun 2020 Suzhou GeneQuantum Healthcare has global patent protection for iLDC technology platform